SPL801- RAPID ACTING ANTIDEPRESSANT

本项目旨在对一种有前景的新型速效抗抑郁药进行临床前研究。治疗抑郁症的标准护理是选择性5-羟色胺再摄取抑制剂(SSRIs)。SSRIs的一个主要缺点是，在早期治疗期间，特别是在年轻患者中，它们很少能有效地减少自杀意念和自杀行为。自杀是英国20-34岁年轻人的主要死因，英国每年登记的自杀人数超过6000人。高达75%的自杀案例与抑郁症有关。这个项目建立在学术研究的基础上，该研究确定了一种快速有效的抗抑郁药物，该药物有望作为一种治疗方法来减少重度抑郁症患者的自杀倾向。人们对药物的物理形态或其对药物配方的适用性知之甚少。该项目的成果是了解可用于制备适当剂型的技术途径，以研究这种药物在人体上的应用，为临床试验铺平道路。

This project is to conduct preclinical research into a promising new rapid-acting antidepressant. The standard of care in treating depression are selective serotonin reuptake inhibitors (SSRIs). A major drawback of SSRIs is that they are rarely effective in reducing suicidal ideation and suicidal behaviour during early treatment, particularly in young patients. Suicide is the leading cause of death in 20-34 year olds in the UK, and over 6000 suicides are registered in the UK each year. As many as 75% of suicide cases are associated with depression. This project builds on academic research which identifies a rapid-acting antidepressant which shows promise as a therapy to reduce suicidality in major depression patients. Very little is known about the physical form of the drug, or its suitability to pharmaceutical formulation. The outcome of this project is to understand the technical avenues available to prepare suitable dosage forms to investigate this drug in humans, paving the way for clinical trials.